Treatment of High PTH Symptoms

Primary Hyperparathyroidism (PHPT)

• Parathyroidectomy is the only curative treatment for PHPT and should be performed in patients meeting specific criteria, including impaired kidney function (GFR < 60 mL/min/1.73 m²) 1
• The American College of Endocrinology recommends surgery for patients with primary hyperparathyroidism who have symptomatic disease, including kidney stones, bone pain, fractures, and neuromuscular symptoms, as well as those with osteoporosis on DEXA scan and hypercalciuria 1
• Minimally invasive parathyroidectomy (MIP) offers shorter operating times, faster recovery, and decreased perioperative costs compared to bilateral neck exploration, and requires confident preoperative localization of a single parathyroid adenoma and intraoperative PTH monitoring 2

Secondary Hyperparathyroidism (in CKD patients)

• The National Kidney Foundation recommends initial medical management for secondary hyperparathyroidism in CKD patients on dialysis, including dietary phosphate restriction, phosphate binders, correction of hypocalcemia with calcium supplementation, and vitamin D sterols (calcitriol, paricalcitol, doxercalciferol) with dosage adjusted according to severity 2
• Strict monitoring is essential, including serum calcium and phosphorus every 2 weeks for 1 month after initiation or dose increase, then monthly, and PTH monthly for at least 3 months, then every 3 months once target levels achieved 3
• Cinacalcet may be considered for persistent secondary hyperparathyroidism despite initial therapy, starting at 30 mg once daily and titrating no more frequently than every 2-4 weeks to target iPTH levels of 150-300 pg/mL, with caution due to potential hypocalcemia and increased QT interval 2

Critical Diagnostic Considerations

• The Endocrine Society recommends confirming the diagnosis biochemically before initiating treatment, including measuring serum calcium (corrected for albumin) and intact PTH simultaneously, and assessing vitamin D status, as vitamin D deficiency can complicate PTH interpretation and cause secondary hyperparathyroidism 1, 3
• PTH assays vary significantly between laboratories and different assay generations have variable sensitivity to PTH fragments, so use assay-specific reference values when interpreting results 1, 3

Management of Asymptomatic Primary Hyperparathyroidism

Diagnosis and Severity Assessment

• The elevated PTH (144 pg/mL) in the setting of hypercalcemia (13 mg/dL) confirms primary hyperparathyroidism, as the PTH is inappropriately elevated or "normal" when it should be suppressed, according to the Endocrine Society 4
• The vitamin D level of 45 ng/mL is adequate, ruling out vitamin D deficiency as a cause of secondary hyperparathyroidism, as per the Endocrine Society guidelines 4

Surgical Planning

• Sestamibi (99Tc-Sestamibi) scan has the highest sensitivity for localizing parathyroid adenomas, as recommended by the American Journal of Kidney Diseases 5

Treatment of High Parathyroid Hormone

Surgical Intervention for Refractory SHPT

• The International Journal of Surgery recommends total parathyroidectomy with or without parathyroid tissue autotransplantation as a surgical option for severe hyperparathyroidism with persistent serum levels of intact PTH >800 pg/mL associated with hypercalcemia and/or hyperphosphatemia refractory to medical therapy, with total parathyroidectomy (TPTX) being superior to TPTX + AT regarding recurrence rates (OR = 0.20; 95%CI, 0.11-0.38; P < 0.01) 6
• Total parathyroidectomy (TPTX) has lower rates of reoperation due to recurrence or persistence (OR = 0.17; 95%CI, 0.06-0.54; P = 0.002) and shorter operative time, but carries a higher risk of hypoparathyroidism (OR = 2.97; 95%CI, 1.09-8.08; P = 0.01) 6

Management of Elevated Calcium and PTH in CKD Patients

Surgical Management in CKD Patients

• Parathyroidectomy in CKD patients on dialysis is reserved for refractory and/or symptomatic hypercalcemia, refractory hyperphosphatemia, severe intractable pruritus, serum calcium × phosphorus product persistently exceeding 70-80 mg/dL with progressive extraskeletal calcifications, and calciphylaxis, as recommended by the American Society of Transplantation 7

Parathyroidectomy for Refractory Secondary Hyperparathyroidism in ESRD

Indications and Surgical Approach

• For ESRD patients on hemodialysis with hyperparathyroidism refractory to medical management, parathyroidectomy is the definitive treatment of choice, as recommended by the American Society of Transplantation 8, 9
• The American Society of Transplantation suggests that parathyroidectomy should be performed when medical management fails, with a strength of evidence based on clinical trials 8, 9

Preoperative Medical Management

• Before proceeding to surgery, ensure adequate medical optimization has been attempted, including medical management with phosphate-binding agents, vitamin D metabolites or analogues, and cinacalcet, as suggested by the American Journal of Transplantation 9

Surgical Options

• All three surgical approaches, including subtotal parathyroidectomy, total parathyroidectomy with autotransplantation, and total parathyroidectomy without autotransplantation, have been advocated with excellent results, according to the American Society of Transplantation 8, 9

Critical Pitfalls to Avoid

• Exclude aluminum-induced bone disease before proceeding to surgery, as this condition requires different management, as recommended by the American Society of Transplantation 8, 9

Management of Hyperparathyroidism

Medical Management of Secondary Hyperparathyroidism

• The Kidney International guideline recommends targeting intact PTH levels in the range of approximately 2 to 9 times the upper normal limit for the assay in CKD G5D patients, and suggests using phosphate binders, correcting hypocalcemia with calcium supplementation, and vitamin D sterols as initial therapy 10
• The Kidney International guideline suggests using calcimimetics, calcitriol, or vitamin D analogs, or a combination of calcimimetics with calcitriol or vitamin D analogs for patients requiring PTH-lowering therapy 10
• Parathyroidectomy is indicated for CKD G3a-G5D patients with severe hyperparathyroidism who fail to respond to medical or pharmacological therapy, according to the Kidney International guideline 10
• The Kidney International guideline recommends using a dialysate calcium concentration between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L) in CKD G5D patients 10